Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References China sales on track to double by 2024 1 GROWTH Group sales evolution USD bn, % cc +18% 0.8 0.7 Strong performance of growth drivers following NRDL inclusion¹ ◉ Solid momentum for Cosentyx® and EntrestoⓇ ■ All key products included in NRDL, outperforming multinational companies by sales growth for those brands ■ Limited exposure to VBP Expanding commercial footprint for additional reach Ramping up activities in lower tier cities and hospitals Increasing cross-functional account management for higher productivity Q3 2020 Q3 2021 ■ Broadening presence in retail and e-pharmacy channels +16% 2.4 1.9 Late stage pipeline to fuel further growth ◉ ◉ ■ EntrestoⓇ HTN, Lucentis® PDR/ROP, Cosentyx® Ped PSO approved in Q3 TafinlarⓇ+MekinistⓇ lung cancer, KisqaliⓇ submitted in Q3 Additional ~50 submissions planned in next 5 years 9M 2020 NRDL National Reimbursement Drug List Cosentyx in Q1/2021 10 Investor Relations | Q3 2021 Results 9M 2021 IL Interleukin HTN Hypertension PDR/ROP - Proliferative Diabetic Retinopathy/ Retinopathy of Prematurity PedPSO - Pediatric Psoriasis 1: EntrestoⓇ NRDL inclusion in Q1/2020, ✓ NOVARTIS | Reimagining Medicine

View entire presentation